Search results for "SHI"

showing 10 items of 9733 documents

Phase I trial of recombinant human tumour necrosis factor alpha in patients with advanced malignancy.

1991

A phase I clinical trial was conducted with recombinant human tumour necrosis factor alpha (rhTNF-alpha) in 62 patients with advanced malignancy refractory to previous standard therapy. rhTNF-alpha was given as a 30 min infusion twice a day at 6 h intervals. A total of 10 different dose levels was escalated in cohorts of 6 patients ranging from 2.5 to 200 micrograms/m2 twice a day for 5 days every second week for a total of 8 weeks followed by a 4-week observation period. Major side-effects of TNF-alpha therapy, seen in almost all patients studied, were fever and chills. As dose-limiting side-effects hypotension and liver toxicity were recorded in 4 of 5 patients treated with 200 micrograms…

AdultBlood PlateletsMalemedicine.medical_specialtyNecrosisAdolescentFeverPhases of clinical researchBlood PressureMalignancyGastroenterologyHemoglobinsLeukocyte CountPharmacokineticsRefractoryInternal medicineNeoplasmsmedicineLeukocytesHumansAgedbiologyDose-Response Relationship Drugbusiness.industryPlatelet CountTumor Necrosis Factor-alphaMiddle Agedmedicine.diseaseRecombinant ProteinsSurgeryOncologybiology.proteinDrug EvaluationTumor necrosis factor alphaChillsFemaleAntibodymedicine.symptombusinessEuropean journal of cancer (Oxford, England : 1990)
researchProduct

Increased thromboxane biosynthesis in type IIa hypercholesterolemia.

1992

BACKGROUND Increased platelet thromboxane (TX)A2 production has been described in type IIa hypercholesterolemia. To verify the relevance of these capacity-related measurements to the actual rate of TXA2 biosynthesis in vivo, we studied the urinary excretion of its major enzymatic metabolites in 46 patients with type IIa hypercholesterolemia and 20 age-matched controls. METHODS AND RESULTS Urinary 11-dehydro-TXB2 and 2,3-dinor-TXB2 were measured by previously validated radioimmunoassays. The excretion rate of 11-dehydro-TXB2 was significantly (p less than 0.001) higher in patients (68.7 +/- 35.1 ng/hr, mean +/- SD) than in controls (22.4 +/- 9.4 ng/hr), with metabolite excretion greater tha…

AdultBlood PlateletsMalemedicine.medical_specialtySimvastatinThromboxaneMetaboliteHypercholesterolemiaExcretionchemistry.chemical_compoundThromboxane A2Physiology (medical)Internal medicinemedicineHumansPlateletPlatelet activationLovastatinAgedbiologyAspirinDose-Response Relationship Drugbusiness.industryCholesterolAnticholesteremic AgentsMiddle AgedEndocrinologychemistrySimvastatinbiology.proteinlipids (amino acids peptides and proteins)FemaleCyclooxygenaseCardiology and Cardiovascular Medicinebusinessmedicine.drugCirculation
researchProduct

Levo folinic acid and 5-fluorouracil plus high dose epidoxorubicin as first line treatment for metastatic breast carcinoma

1993

Twenty-two women affected by metastatic breast carcinoma have been treated with a combination of levo folinic acid 100 mg/m 2 plus 5-fluorouracil 450 mg/m 2 i.v. on day 1-2, and epidoxorubicin 75-90 mg/m 2 on day 2. This treatment cycle was repeated every 21-28 days. No patients had previously received chemotherapy for metastatic disease. Fourteen patients (64%) showed a major objective response with 3 complete (14%) and 11 partial responses (50%). Three patients showed a stabilization of disease and 5 (23%) progressed. All patients received ondansetron as antiemetic treatment which led to complete protection from vomiting in 68% of cases. Grade 1-2 diarrhea was recorded in 27% of the patie…

AdultCancer Research5-flurouracilDose-Response Relationship DrugLevo folinic acidCarcinomaLeucovorinBreast NeoplasmsMiddle AgedBreast cancerCarcinoma Intraductal NoninfiltratingOncologyEpidoxorubicinAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleFluorouracilAgedEpirubicin
researchProduct

A Phase I Study of Intravenous LBH589, a Novel Cinnamic Hydroxamic Acid Analogue Histone Deacetylase Inhibitor, in Patients with Refractory Hematolog…

2006

Abstract Purpose: LBH589 is a novel histone deacetylase inhibitor that inhibits proliferation and induces apoptosis in tumor cell lines. In this phase I study, LBH589 was administered i.v. as a 30-minute infusion on days 1 to 7 of a 21-day cycle. Experimental Design: Fifteen patients (median age, 63 years; range, 42-87 years) with acute myeloid leukemia (13 patients), acute lymphocytic leukemia (1 patient), or myelodysplastic syndrome (1 patient) were treated with LBH589 at the following dose levels (mg/m2): 4.8 (3 patients), 7.2 (3 patients), 9.0 (1 patient), 11.5 (3 patient), and 14.0 (5 patients). The levels of histone acetylation were measured using quantitative flow cytometry and plasm…

AdultCancer ResearchIndolesMaximum Tolerated Dosemedicine.drug_classApoptosisPharmacologyHydroxamic AcidsDrug Administration ScheduleHistonesStructure-Activity Relationshipchemistry.chemical_compoundPredictive Value of TestsPanobinostatAcute lymphocytic leukemiaPanobinostatBiomarkers TumormedicineHumansEnzyme InhibitorsAgedCell ProliferationAged 80 and overDose-Response Relationship Drugbusiness.industryHistone deacetylase inhibitorArea under the curveQTcF ProlongationMyeloid leukemiaMiddle AgedPrecursor Cell Lymphoblastic Leukemia-Lymphomamedicine.diseaseHypokalemiaHistone Deacetylase InhibitorsLeukemiaTreatment OutcomeOncologychemistryCinnamatesLeukemia MyeloidMyelodysplastic SyndromesAcute DiseaseInjections IntravenousImmunologymedicine.symptombusinessFollow-Up StudiesClinical Cancer Research
researchProduct

Successful adenovirus-mediated wild-type p53 gene transfer in patients with bladder cancer by intravesical vector instillation.

2002

PURPOSE: To study safety, feasibility, and biologic activity of adenovirus-mediated p53 gene transfer in patients with bladder cancer. PATIENTS AND METHODS: Twelve patients with histologically confirmed bladder cancer scheduled for cystectomy were treated on day 1 with a single intratumoral injection of SCH 58500 (rAd/p53) at cystoscopy at one dose level (7.5 × 1011 particles) or a single intravesical instillation of SCH 58500 with a transduction-enhancing agent (Big CHAP) at three dose levels (7.5 × 1011 to 7.5 × 1013 particles). Cystectomies were performed in 11 patients on day 3, and transgene expression, vector distribution, and biologic markers of transgene activity were assessed by m…

AdultCancer ResearchPathologymedicine.medical_specialtymedicine.medical_treatmentGenetic enhancementGenetic VectorsUrologyCystectomyAdenoviridaeCystectomymedicineHumansNeoplasm InvasivenessAgedDNA PrimersBiologic markerAged 80 and overUrinary bladderBladder cancermedicine.diagnostic_testDose-Response Relationship Drugbusiness.industryReverse Transcriptase Polymerase Chain ReactionGenetic transferGene Transfer TechniquesCystoscopyGenetic TherapyMiddle Agedmedicine.diseaseGenes p53medicine.anatomical_structureAdministration IntravesicalOncologyUrinary Bladder NeoplasmsImmunohistochemistrybusinessJournal of clinical oncology : official journal of the American Society of Clinical Oncology
researchProduct

Weekly administration of gemcitabine plus docetaxel in patients with advanced breast cancer: a phase 1 study.

2002

<i>Objective:</i> This study was designed to determine the maximum tolerable dose (MTD) of gemcitabine plus docetaxel, both given on a weekly schedule, in patients with pretreated metastatic breast cancer (MBC). <i>Methods:</i> Heavily pretreated patients with MBC, aged 18–75 years with World Health Organization performance status of 0–2 were enrolled. Three escalating weekly doses of docetaxel (30, 35 and 40 mg/m<sup>2</sup>) followed by a weekly fixed dose of gemcitabine, 800 mg/m<sup>2</sup>, were administered on days 1, 8 and 15 of a 28-day cycle. Dose-limiting toxicity (DLT) included grade >3 hematologic toxicity and grade >2 stomat…

AdultCancer Researchmedicine.medical_specialtyLung NeoplasmsPaclitaxelmedicine.drug_classmedicine.medical_treatmentBone NeoplasmsBreast NeoplasmsDocetaxelWorld Health OrganizationAntimetaboliteGastroenterologyDeoxycytidineInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansNeoplasm MetastasisAgedChemotherapyPerformance statusDose-Response Relationship Drugbusiness.industryLiver NeoplasmsGeneral MedicineMiddle Agedmedicine.diseaseMetastatic breast cancerGemcitabineGemcitabineSurgeryRegimenTreatment OutcomeOncologyDocetaxelLymphatic MetastasisToxicityFemaleTaxoidsbusinessmedicine.drugOncology
researchProduct

Cancer consequences of the Chernobyl accident in Europe outside the former USSR: A review

1996

The accident which occurred during the night of April 25-26, 1986 in reactor 4 of the Chernobyl nuclear power plant in the Ukraine released considerable amounts of radioactive substances into the environment. Outside the former USSR, the highest levels of contamination were recorded in Bulgaria, Austria, Greece and Romania, followed by other countries of Central, Southeast and Northern Europe. Studies of the health consequences of the accident have been carried out in these countries, as well as in other countries in Europe. This report presents the results of a critical review of cancer studies of the exposed population in Europe, carried out on the occasion of the 10th anniversary of the …

AdultCancer Researchmedicine.medical_specialtyNeoplasms Radiation-InducedAdolescentEnvironmental protectionNeoplasmsmedicineHumansThyroid NeoplasmsChildSocioeconomicsAccident (philosophy)AgedLeukemia Radiation-InducedHealth consequencesIncidencePublic healthInfant NewbornInfantDose-Response Relationship RadiationEnvironmental exposureMiddle Agedcancer ; thyroid ; leukaemia ; nuclear accident ; ChernobylEuropeGeographyOncologyChild PreschoolRadioactive Hazard ReleaseUkrainePower PlantsInternational Journal of Cancer
researchProduct

Central action of cinnarizine and flunarizine: A saccadic eye movement study

1994

The mechanism of action of flunarizine (FZ) and cinnarizine (CZ) on the CNS is not fully understood. Computer analysis of saccadic eye movements (SEM) provides a sensitive and objective method for evaluating drug effect on the function of specific brain structures. This study aimed to assess the effect of a single oral dose of FZ (20 mg) and CZ (150 mg) on CNS function by means of computer analysis of SEM. Ten healthy volunteers were studied according to a double-blind, cross-over, placebo-controlled design. Peak saccadic velocity (PSV), which is related to the function of a specific group of burst neurons located in the brain stem, was significantly reduced by FZ. No significant effect of …

AdultCentral Nervous SystemMaleCinnarizineCentral nervous systemAdministration OralCinnarizinePlacebosDouble-Blind MethodmedicineSaccadesHumansPharmacology (medical)FlunarizinePharmacologyCross-Over StudiesDose-Response Relationship Drugbusiness.industryEye movementCalcium Channel BlockersSaccadic maskingElectrophysiologymedicine.anatomical_structureMechanism of actionSaccadeNeurology (clinical)medicine.symptombusinessNeuroscienceFlunarizinemedicine.drug
researchProduct

Tactical Aspects of a National University Taekwondo Championship in Relation to Round and Match Outcome

2015

The aims of this study were to analyze tactical behavior (direct attacks and indirect attacks, in addition to anticipatory, simultaneous, and posterior counterattacks) according to competition round and match, and to compare tactics of competitors (winners and nonwinners) in a university taekwondo championship. The analysis included 334 individual performances from 204 athletes over 169 bouts in the National University Championship. A 2-way repeated measure analysis of variance was conducted with “round” (at 3 levels: first, second, and third) as the within-subject factor and match outcome (at 2 levels: winning and nonwinning) as the between-subject factor. The results of this study show th…

AdultCompetitive BehaviorAdolescentbiologyAthletesApplied psychologyRepeated measures designPhysical Therapy Sports Therapy and RehabilitationGeneral Medicinebiology.organism_classificationOutcome (game theory)Young AdultAthletesHumansOrthopedics and Sports MedicineChampionshipPsychologyMartial ArtsJournal of Strength and Conditioning Research
researchProduct

Attachment anxiety and avoidance and perceptions of group climate: an actor-partner interdependence analysis.

2012

There is a lack of research examining group members’ attachment styles and group climate perceptions in the context of the attachment styles and group climate perceptions of the other group members. In the current study, the actor–partner interdependence model (APIM) was used to examine the relationships among (a) a group member’s attachment pattern, (b) the aggregated attachment patterns of the other group members, (c) a group member’s perceptions of the group’s climate, and (d) the aggregated group climate perceptions of the other group members. One hundred ten Italian graduate students in six 10-session interpersonal growth groups were studied. Group members filled out the Attachment Sty…

AdultCounselingMalegroup climate attachment avoidance and anxiety actor–partner analysisgenetic structuresSocial PsychologyContext (language use)Interpersonal communicationModels PsychologicalSocial Environmentbehavioral disciplines and activitiesConflict PsychologicalInterpersonal relationshipYoung AdultSettore M-PSI/08 - Psicologia ClinicaAttachment theorymedicineHumansInterpersonal RelationsSocial BehaviorObject AttachmentSocial perceptionGroup conflictGeneral MedicineMiddle AgedObject AttachmentGroup ProcessesPsychiatry and Mental healthClinical PsychologyItalySocial PerceptionPsychotherapy GroupAnxietyFemalesense organsmedicine.symptomPsychologySocial psychologypsychological phenomena and processesJournal of counseling psychology
researchProduct